| Politician | Action | Description | Traded |
|---|---|---|---|
| Buy | DELANEY ANIMAL HEALTH INCPOR | Jan 7, 2024 | |
| Sell | BEAM GLOBAL COM STK $0.001 P | Jan 29, 2021 | |
| Sell | Beam Global | Nov 5, 2020 | |
| Buy | Beam Global [BEAM] [ST] | Sep 15, 2020 |
This page tracks congressional stock trading activity in Beam Therapeutics Inc. (BEAM) in the Healthcare sector. Disclosed Capitol has indexed 4 disclosed congressional trades involving BEAM. Every trade is sourced from official STOCK Act financial disclosure filings — the same primary records the Senate and House are required to publish. The full trade list with politician names, transaction types, amount ranges, and disclosure dates is below, alongside cross-references to any related lobbying activity, federal contracts, and committee assignments.
As of January 2024 — Disclosed Capitol has tracked 4 disclosed congressional trades in Beam Therapeutics Inc. (BEAM) — 2:2 buy-heavy ratio — led by Ro Khanna (D).
| Date | Politician | Party | Action | Amount |
|---|---|---|---|---|
| Jan 7, 2024 | Ro Khanna | D | Buy | $1,001 - $15,000 |
| Jan 29, 2021 | Ro Khanna | D | Sell | $1,001 - $15,000 |
| Nov 5, 2020 | Brian Mast | R | Sell | $35,001 - $50,000 |
| Sep 15, 2020 | Brian Mast | R | Buy | $15,001 - $50,000 |
Across the 4 disclosed congressional trades in Beam Therapeutics Inc. (BEAM), members of Congress have reported 2 buys and 2 sells. The average 30-day alpha vs. the S&P 500 is -15.64%.
As of October 2026, corporate insiders at Beam Therapeutics Inc. have filed 7 SEC Form 4 transactions in BEAM over the past 12 months — including 4 sells worth $1.6M.
| Date | Insider | Action | Value |
|---|---|---|---|
| 2026-10-16 | Evans John M. — CEO | Option Exercise | $26K |
| 2026-10-16 | Evans John M. — CEO | Sale | $600K |
| 2026-10-15 | Evans John M. — CEO | Option Exercise | $26K |
| 2026-10-15 | Evans John M. — CEO | Sale | $589K |
| 2026-10-01 | Cavanagh Bethany J — SVP, Finance and Treasurer | Sale | $5K |
| 2026-09-24 | Ciaramella Giuseppe — President | Gift | — |
| 2026-07-27 | Simon Amy — Chief Medical Officer | Sale | $429K |
Insider transactions are parsed from SEC Form 4 filings and shown alongside the congressional trades above. Institutional 13F positions are tracked separately on the institutional holdings page.
For fiscal year 2025, Beam Therapeutics Inc. reported revenue of $377.7M and net income of -$132.5M, per SEC filings.
Most recent reported quarter: Q2 FY2026 — revenue $32.2M, net income -$217.0M.
Figures come from SEC financial statement filings. The full annual and quarterly statement history is in the Financials tab above.